Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Badger Meter Inc (BMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Badger Meter Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.95 (market cap $29.60B), while Badger Meter Inc trades at $134.3 (market cap $3.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.5× Badger Meter Inc's market cap, and Badger Meter Inc pays a 1.18% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BMI | |
|---|---|---|
Market Cap | $29.60B | $3.93B |
Sector | Health | Technology |
52-Week High | $491.22 | $193.09 |
52-Week Low | $205.48 | $113.41 |
Enterprise Value | $27.56B | $3.84B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Badger Meter (BMI) trades at $133.63, down 2.06% amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 14.27% net margin and 18.48% ROE, but faces headwinds from recent securities class action lawsuits and declining revenue projections for 2026. Technical indicators suggest bearish momentum with resistance at $137-$139 levels.
While BMI maintains solid fundamentals and analyst consensus targets $155.20 (16% upside), near-term risks include legal uncertainties and earnings volatility. The company's water technology focus provides defensive characteristics, but investors should weigh class action litigation risks against the stock's valuation premium (P/E 31.78).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Badger Meter Inc
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →
